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Abstract 
MRI-visible perivascular spaces are a neuroimaging marker of cerebral small vessel disease. 
Their location may relate to the type of underlying small vessel pathology: those in the white 
matter centrum semi-ovale have been associated with cerebral amyloid angiopathy, whilst 
those in the basal ganglia have been associated with deep perforating artery arteriolosclerosis. 
Since cerebral amyloid angiopathy is an almost invariable pathological finding in 
Alzheimer’s disease, we hypothesized that MRI-visible perivascular spaces in the centrum 
semi-ovale would be associated with a clinical diagnosis of Alzheimer’s disease, whereas 
those in the basal ganglia would be associated with subcortical vascular cognitive 
impairment. We also hypothesised that MRI-visible perivascular spaces in the centrum semi-
ovale would be associated with brain amyloid burden, as detected by amyloid-PET using 
[11C] Pittsburgh B compound (PiB-PET). 226 patients (Alzheimer’s disease n=110; 
subcortical vascular cognitive impairment n=116) with standardised MRI and PiB-PET 
imaging were included. MRI-visible perivascular spaces were rated using a validated 4-point 
visual rating scale, and then categorised by severity (“none/mild”, “moderate” or 
“frequent/severe”). Univariable and multivariable regression analyses were performed. Those 
with Alzheimer’s disease related cognitive impairment were younger, more likely to have a 
positive amyloid-PET scan and carry at least one Apolipoprotein E ε4 allele; those with 
subcortical vascular cognitive impairment were more likely to have hypertension, diabetes 
mellitus, hyperlipidaemia, prior stroke, lacunes, deep microbleeds, and carry the 
Apolipoprotein E ε3 allele. In adjusted analyses, the severity of MRI-visible perivascular 
spaces in the centrum semi-ovale was independently associated with clinically diagnosed 
Alzheimer’s disease (frequent/severe grade Odds Ratio, OR, 7.696.26, 95% CI 1.66 to 
23.584.29 to 20.71; p=0.00030.017, compared with none/mild grade), whereas the severity of 
MRI-visible perivascular spaces in the basal ganglia was associated with clinically diagnosed 
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subcortical vascular cognitive impairment and negatively predicted Alzheimer’s disease 
(frequent/severe grade OR 0.035, 95% CI 0.01 00 to 0.4744; p=0.00904, compared with 
none/mild grade). MRI-visible perivascular space severity in either location did not predict 
amyloid-PET positivity. These findings provide further evidence that the anatomical 
distribution of MRI-visible perivascular spaces may reflect the underlying cerebral small 
vessel disease. Using MRI-visible perivascular space location and severity together with 
other imaging markers may improve the diagnostic value of neuroimaging in memory clinic 
populations, in particular in differentiating between clinically diagnosed  Alzheimer’s and 
subcortical vascular cognitive impairment.  
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Abbreviations: 
Aβ Amyloid beta 
AD Alzheimer’s disease  
ADCI Alzheimer’s disease related cognitive impairment (aMCI & AD)  
aMCI Amnestic mild cognitive impairment 
APOE Apolipoprotein E 
BG Basal ganglia 
CAA Cerebral amyloid angiopathy 
CI Confidence Interval 
CMB Cerebral microbleed 
CSO Centrum semi-ovale 
cSS Cortical superficial siderosis 
ICH Intracerebral haemorrhage 
IQR Interquartile range 
OR Odds ratio 
PiB 11-Carbon based Pittsburgh compound B 
PVS Perivascular space (MRI-visible) 
SD Standard deviation 
SVaD Subcortical vascular dementia 
svMCI Subcortical vascular MCI 
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SVCI Subcortical vascular cognitive impairment (svMCI & SVaD)  
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Introduction 
Small vessel diseases of the brain are an important cause of stroke and dementia (Pantoni, 
2010; Bath and Wardlaw, 2015). Our ability to accurately identify these diseases using 
neuroimaging markers has improved considerably in recent years (Wardlaw et al., 2013c), 
with increasing interest in the role of small vessel pathology in traditionally “non-vascular” 
dementias, such as Alzheimer’s disease (AD). The most common age-related cerebral small 
vessel disease subtypes are: arteriolosclerosis and related processes affecting deep perforating 
arteries (often termed hypertensive arteriopathy); and cerebral amyloid angiopathy (CAA) 
(Pantoni, 2010). Arteriolosclerosis is associated with hypertension, diabetes and increasing 
age, and “vascular” dementia (the most common form of which is subcortical vascular 
cognitive impairment, SVCI), whereas CAA is the result of amyloid-beta (Aβ) deposition in 
the walls of small to medium vessels in the cortex and leptomeninges, and found in over 90% 
of those with AD (Charidimou et al., 2012). As well as being a risk factor for spontaneous 
intracerebral haemorrhage (Samarasekera et al., 2012), CAA can result in cognitive deficits 
independently of AD (Arvanitakis et al., 2011; Boyle et al., 2015; Reijmer et al., 2015), 
although the exact interaction between these two processes remains unclear. Traditionally AD 
and SVCI have been described as having distinct neuroimaging profiles (Wardlaw et al., 
2013b; Greenberg et al., 2014), but clinically differentiating between the two remains 
difficult, as both the cognitive symptoms and the imaging findings frequently overlap (Lee et 
al., 2011; Wardlaw et al., 2013a; Wardlaw et al., 2013b; Greenberg et al., 2014; Lee et al., 
2014). Given this, identifying new markers that further improve our ability to discriminate 
between AD and SVCI remains both relevant and important, in particular with regard to 
recruitment for clinical trials investigating pharmacological interventions (Ahmed et al., 
2014; Andrieu et al., 2015).   
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MRI-visible perivascular spaces (PVS) - sometimes termed Virchow-Robin spaces, type 3 
lacunes and état crible - are hypothesised to result from an enlargement of the potential space 
within the wall of a cerebral blood vessel, possibly secondary to impaired interstitial fluid 
drainage (Wardlaw et al., 2013b; Weller et al., 2015). Whereas enlargement in the basal 
ganglia (BG-PVS) appears to be associated with markers of arteriolosclerosis, enlargement of 
PVS in the white matter centrum semi-ovale (CSO-PVS) appears to be associated with 
cerebral Aβ pathologies, both AD and CAA (Charidimou et al., 2013a; Charidimou et al., 
2013b; Martinez-Ramirez et al., 2013). Neuropathological studies have demonstrated that the 
frequency and severity of white matter PVS is greater in AD than controls, and this was 
associated with brain Aβ load, severity of CAA and Apolipoprotein E (APOE) ε4 presence 
(Roher et al., 2003). The association of AD and increased white matter PVS volume has also 
been demonstrated using neuroimaging (Ramirez et al., 2015). PVS in the centrum semi-
ovale (CSO-PVS) are associated with CAA-related intracerebral haemorrhage (ICH) 
(Charidimou et al., 2013b; Charidimou et al., 2014b) and its “haemorrhagic” markers, 
namely lobar microbleeds (Martinez-Ramirez et al., 2013; Yakushiji et al., 2014) and cortical 
superficial siderosis (Charidimou et al., 2014a). Indeed, a recent study using post-mortem 7-
Tesla MR in CAA-related ICH found an association between juxta-cortical PVS enlargement 
and the histopathological grade of CAA in the overlying cortex (van Veluw et al., 2015). In 
addition, a small study of patients with CAA-related ICH and healthy controls found an 
association between amyloid-PET burden (as measured using 11-Carbon based Pittsburgh 
compound B, PiB) and CSO-PVS (Charidimou et al., 2015). This makes PVS topography in 
certain clinical contexts a promising new marker of cerebral small vessel diseases. However, 
the relationships between PVS topography, amyloid deposition and clinical dementia 
syndromes (AD and SVCI) are not well understood.  
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We aimed to further evaluate this association of PVS location with small vessel disease type 
in a cohort of patients with AD related cognitive impairment (ADCI; either AD or AD mild 
cognitive impairment) and SVCI (either subcortical vascular dementia or subcortical vascular 
mild cognitive impairment). We hypothesised that ADCI is associated with CSO-PVS (as 
these patients are likely to have CAA), but not BG-PVS, which instead is associated with 
SVCI (and arteriolosclerosis). We also hypothesised that, given the CSO-PVS are associated 
with cerebral Aβ diseases, CSO-PVS is associated with PiB positivity, whereas BG-PVS 
would not demonstrate any such association.  
 
 
Materials & Methods 
Participants 
We prospectively recruited 251 subjects with cognitive impairment who underwent PiB-PET 
and structural brain MRI, between July 2007 and July 2011. We included 45 patients with 
amnestic mild cognitive impairment (aMCI), 69 with probable AD dementia, 67 with 
subcortical vascular MCI (svMCI), and 70 with subcortical vascular dementia (SVaD); all 
patients had been clinically diagnosed at Samsung Medical Center. Of these, 226 subjects 
were included in the current study, with exclusions made either due to imaging being 
unavailable (n = 20) or too degraded by motion artefact to be interpreted (n = 5). Probable 
AD dementia patients fulfilled diagnostic criteria proposed by the National Institute of 
Neurological and Communicative Disorders and Stroke and the AD and Related Disorders 
Association (McKhann et al., 1984). Patients with SVaD met the diagnostic criteria for 
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vascular dementia as determined by the Diagnostic and Statistical Manual of Mental 
Disorders (Fourth Edition), and also fulfilled the imaging criteria for SVaD proposed by 
Erkinjuntti et al (Erkinjuntti et al., 2000). Patients with aMCI and svMCI met Petersen’s 
criteria for MCI with modifications (Seo et al., 2009).  All svMCI and SVaD patients had 
severe white matter hyperintensities (WMH) on their MRI scans, which was defined as a cap 
or band (periventricular WMH) ≥10mm and deep WM lesions (deep WMH) ≥25mm, as 
modified from the Fazekas ischemia criteria (Fazekas et al., 1993).  All aMCI and AD 
patients were classified as having minimal (periventricular WMH <5mm and deep WMH 
<5mm) or moderate WMH (between minimal and severe grades). These WMH definitions 
are in line with those recently proposed to describe WMH of presumed vascular origin 
(Wardlaw et al., 2013c). Patients with aMCI or AD were considered to have AD-related 
cognitive impairment (ADCI), whereas those with svMCI or SVaD were considered to have 
subcortical vascular cognitive impairment (SVCI). We excluded patients with territorial 
infarctions and those with WMH due to radiation injury, multiple sclerosis, vasculitis, or 
leukodystrophy. All patients completed a clinical interview and neurological examination. 
Blood tests included a complete blood count, blood chemistry test, vitamin B12/folate 
measurement, syphilis serology, thyroid function test, and APOE genotyping.  
 
We obtained written consent from each patient, and the study protocol was approved by the 
Institutional Review Board of the Samsung Medical Center.  
 
PiB-PET acquisition and data analysis  
[11C] PiB-PET scanning was performed on all participants at Samsung or Asan Medical 
Center using a Discovery STe PET/CT scanner (GE Medical Systems, Milwaukee, WI) in 3-
dimensional scanning mode that examined 35 slices of 4.25-mm thickness spanning the entire 
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brain. [11C] PiB was injected into an antecubital vein as a bolus with a mean dose of 420 
MBq (i.e., range 259–550 MBq). A CT scan was performed for attenuation correction 60 
minutes after injection. A 30-minute emission static PET scan was then initiated. The specific 
radioactivity of [11C] PiB at the time of administration was more than 1,500 Ci/mmol for 
patients and the radiochemical yield was more than 35%. The radiochemical purity of the 
tracer was more than 95% in all PET studies. 
 
PiB PET images were co-registered to individual MRIs, which were normalized to a T1-
weighted MRI template. Using these parameters, MRI co-registered PiB PET images were 
normalized to the MRI template. The quantitative regional values of PiB retention on the 
spatially normalized PiB images were obtained by an automated VOIs analysis using the 
automated anatomical labeling (AAL) atlas. Data processing was performed using SPM 
Version 5 (SPM5) within Matlab 6.5 (MathWorks, Natick, MA). 
 
To measure PiB retention, we used the cerebral cortical region to cerebellum uptake ratio. 
The cerebellum was used as a reference region as it did not show group differences. We 
selected 28 cortical VOIs from left and right hemispheres using the AAL atlas. The cerebral 
cortical VOIs that were chosen for this study consisted of the bilateral frontal (superior and 
middle frontal gyri, the medial portion of superior frontal gyrus, the opercular portion of 
inferior frontal gyrus, the triangular portion of inferior frontal gyrus, supplementary motor 
area, orbital portion of the superior, middle, and inferior orbital frontal gyri, rectus and 
olfactory cortex), posterior cingulate gyri, parietal (superior and inferior parietal, 
supramarginal and angular gyri, and precuneus), lateral temporal (superior, middle and 
inferior temporal gyri, and heschl gyri), and occipital (superior, middle, and inferior occipital 
gyri, cuneus, calcarine fissure, and lingual and fusiform gyri). Regional cerebral cortical 
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uptake ratios were calculated by dividing each cortical VOI’s uptake ratio by the mean uptake 
of the cerebellar cortex (cerebellum crus1 and crus2). Global PiB uptake ratio was calculated 
from the volume-weighted average uptake ratio of bilateral 28 cerebral cortical VOIs. 
Patients were considered PiB-positive if their global PiB retention ratio was over 1.5 from the 
mean of the normal control (Lee et al., 2011).  
 
MR imaging techniques  
Standardized T1, T2, T2* gradient echo (GRE), and 3D fluid-attenuated inversion recovery 
(FLAIR) images were acquired from all subjects at Samsung Medical Center using the same 
3.0T MRI scanner (Philips 3.0T Achieva). In all subjects, these images were obtained in one 
session and all MR images were obtained in the same orientation and slice positions. T2* 
GRE-MRI were obtained using the following parameters: axial slice thickness, 5.0mm; inter-
slice thickness, 2mm; TR, 669ms; TE 16ms; flip angle, 18°, and matrix size of 560x 560 
pixels. We acquired the 3D FLAIR images with the following imaging parameters: axial slice 
thickness of 2 mm; no gap; TR of 11000 msec; TE of 125 msec; flip angle of 90°; and matrix 
size of 512 × 512 pixels.  
 
Measurement of WMH volume  
 WMH volume (in millilitres) was quantified on FLAIR images using an automated method 
(Jeon et al., 2011). Because the contrasting properties of FLAIR images allow automated 
segmentation and classification of WMH (Sachdev et al., 2004), we used FLAIR images to 
quantify WMH. The procedures for measuring regional WMH volume have been previously 
described (Jeon et al., 2011). First, we extracted the WMH candidate regions using T1-
weighted images to avoid misclassification in the subarachnoid space and CSF interface, 
which cannot be excluded by intensity threshold or the conventional brain extraction tools. 
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Second, in order to extract WMH, a threshold method was applied to the FLAIR images after 
using the WMH candidate mask. Even though the threshold value was selected after intensity 
normalization, segmented results could contain the false positive or negative depending on 
the extent of WMH. Therefore, if the results were found to contain an error, the threshold 
value was reselected through visual inspection by two raters. 
 
Lacune assessment on MRI 
A lacune was defined as a lesion ≥3mm and ≤15mm in diameter with low signal on T1 
imaging, high signal on T2-weighted imaging, and with a perilesional halo on FLAIR 
imaging. Two experienced neurologists who were blinded to the patients’ clinical data 
reviewed the number and location of the lacunes on 80 axial FLAIR slices. This meets the 
recently proposed definition of a lacune of presumed vascular origin (Wardlaw et al., 2013c). 
Two neurologists manually counted the number of lacunes, with a kappa value of 0.78.  
 
Analysis of CMBs on gradient echo MRI  
CMBs were defined as lesions ≤10mm in diameter and were also defined using criteria 
proposed by Greenberg et al.(Greenberg et al., 2009).  Two experienced neurologists, who 
were blinded to patient data, reviewed the number and location of CMBs on 20 T2 GRE-MRI 
axial slices. The two neurologists had an agreement kappa value for the presence of CMBs of 
0.92, and a consensus was reached in any case of discrepancy.  
 
CMBs were counted in four lobar regions (frontal, temporal, parietal, occipital) and also in 
deep brain regions. A lobar region was defined as tissue ≤10 mm from the brain surface.  
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Quantification of PVS 
PVS were defined and rated on axial T2-weighted MR images, according to STandards for 
ReportIng Vascular changes on nEuroimaging (STRIVE) (Wardlaw et al., 2013c), by a 
trained observer who was blinded to the clinical information (GB) using a validated 4-point 
visual rating scale (0 = no PVS, 1 = <10 PVS, 2 = 11-20 PVS, 3 = 21-40 PVS and 4 = >40 
PVS) in the basal ganglia and centrum semi-ovale (cerebral hemisphere white matter) 
(Maclullich et al., 2004; Doubal et al., 2010). Rating was carried out on a single pre-defined 
slice (first slice above the anterior commissure in the basal ganglia; the first slice above the 
level of the lateral ventricles for the centrum semi-ovale). Both hemispheres were counted, 
and the hemisphere with the highest score was recorded. Severity was defined as “none/mild” 
(equivalent to rating scale categories 0 and 1), “moderate” (rating scale category 2), and 
“frequent/severe” (rating scale categories 3 and 4) in order to generate groups of a similar 
size for meaningful subsequent statistical analysis.  Figure 1 demonstrates PVS examples of 
each severity grade in both locations. 
 
Statistical Analysis 
Baseline characteristics were compared using Chi-squared or Fishers exact tests for 
categorical variables, independent t-tests for normally distributed continuous variables and 
Mann-Whitney U tests for continuous variables that were not normally distributed. PVS (both 
CSO-PVS and BG-PVS) were considered as categorical variables, subdivided by severity as 
described above. Univariable and multivariable logistic regression analyses were performed; 
variables of interest in univariable analysis were included in the multivariable models. WMH 
volume and lacune burden were not included in the analysis for predictors of diagnosis, as 
these variables had been used to make the original clinical diagnosis.  
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Statistical analysis was performed with Stata (Version 11.2). 
 
Results 
PVS topography as a predictor of clinical diagnosis  
The comparison of baseline characteristics of the ADCI and SVCI groups are shown in Table 
1. Those in the ADCI group were younger (a mean 70.3 years vs 73.8 years, p = 0.0012), 
more likely to be PiB positive (78.2% vs 29.3%, p <0.0001) and carry the APOE ε4 allele 
(48.6% vs 25.7%, p <0.0001). Those in the SVCI group were more likely to have 
hypertension (77.6% vs 47.3%, p <0.0001), diabetes mellitus (25.9% vs 13.6%, p = 0.021), 
hyperlipidemia (36.2% vs 23.6%, p = 0.039), and prior stroke (26.7% vs 5.4%, p <0.0001). 
They were also more likely to carry the APOE ε3 allele (97.4% vs 86.9%, p = 0.004) and 
have lacunes (median 9 vs 0, p <0.0001) and deep CMBs (53.5% vs 6.5%, p <0.0001).  
In univariable logistic regression analysis, increasing CSO-PVS severity was a positive 
predictor of ADCI; individuals with moderate CSO-PVS had an OR of 4.16 (95% CI: 2.08 to 
8.29) and those with frequent/severe CSO-PVS had an OR of 9.43 (95% CI: 4.29 to 20.71) 
compared to those with none/mild CSO-PVS (Table 2). Increasing severity of BG-PVS was 
negatively associated with ADCI (i.e. positively associated with a clinical diagnosis of 
SVCI); individuals with moderate BG-PVS had an OR for ADCI of 0.10 (95% CI: 0.04 to 
0.26) and those with frequent/severe BG-PVS had an OR of 0.06 (95% CI: 0.01 to 0.47) 
compared to those with none/mild BG-PVS. After adjustment for other confounding 
variables, all of these associations remained: increasing CSO-PVS severity was a positive 
predictor of clinically diagnosed ADCI (none/mild as reference group: moderate severity, OR 
5.403.57, 95% CI 1.17 to 10.892.08 to 8.29; frequent/severe, OR 6.267.69, 95% CI 1.66 to 
23.584.29 to 20.71). Increasing severity of BG-PVS was negatively associated with ADCI 
and thus predictive of clinically diagnosed SVCI (none/mild as reference group: moderate 
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severity, OR 0.2614, 95% CI 0.074 to 1.01)0.26; frequent/severe, OR 0.035, 95% CI 0.001 to 
0.447). Younger age, PiB positivity, the absence of hyperlipidaemia and number of lacunes 
the absence of deep CMBs were also associated with a diagnosis of ADCI after adjustment.  
 
PVS topography as a predictor of PiB positivity  
The baseline characteristics of the PiB positive and negative groups are given in Table 3. 
Those in the PiB positive group were more likely to have a diagnosis of ADCI (71.7% vs 
22.6%, p <0.0001), carry the APOE ε4 allele (53.9% vs 17.5%, p <0.0001) and have cSS, 
although the numbers were small (5.8% vs 0.9%, p = 0.047). They were less likely to have 
hypertension (50.0% vs 77.4%, p <0.0001), diabetes mellitus (15.0% vs 25.5%, p = 0.049), 
previous stroke (8.3% vs 25.5%, p = 0.001) and the APOE ε3 allele (86.3% vs 99.0%, P 
<0.0001). They were had a lower WMH volume (median 5.2ml vs 29.9ml, p <0.00001), 
fewer lacunes (median 0 vs 7, p <0.00001) and a lower presence of deep microbleeds (16.8% 
vs 46.7%, p <0.0001).  
In univariable logistic regression analysis increasing CSO-PVS severity was a positive 
predictor of PiB positivity; individuals with moderate CSO-PVS had an OR of 1.37 (95% CI: 
0.74 to 2.54) and those with frequent/severe CSO-PVS had an OR of 2.50 (95% CI: 1.24 to 
5.04) compared to those with none/mild CSO-PVS, respectively (Table 4). However, after 
adjustment for other factors, there was no relationship between CSO-PVS severity and PiB 
positivity. BG-PVS severity was not associated with PiB positivity. The only variables that 
remained independently associated with PiB positivity were ADCI diagnosis, presence of the 
APOE ε4 allele and number of lacunes.  
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Discussion 
CSO-PVS severity is strongly associated with clinically diagnosed ADCI whereas BG-PVS 
severity predicts clinically diagnosed SVCI. However, CSO-PVS severity was not 
independently associated with PiB positivity. There are two possible interpretations of this 
lack of independent association between CSO-PVS with PiB amyloid retention: either CSO-
PVS are associated with ADCI as a marker of amyloid pathology that cannot be accurately 
resolved by amyloid-PET, or CSO-PVS are indicative of an amyloid-independent pathology.  
Our findings are consistent with previous findings of an association between CSO-PVS and 
both AD and CAA, both of which are associated with Aβ deposition (Charidimou et al., 
2012). One reason for the apparent lack of independent association between CSO-PVS and 
PiB might  be that PiB-PET is unable to resolve smaller blood vessels affected by CAA. This 
is supported by neuropathological evidence that, although severity of CAA does appear 
associated with CSO-PVS in AD, the CAA affected vessels are predominantly less than 
500µm in diameter, which may be too small to be identified using PiB-PET (Roher et al., 
2003). Alternatively, the PiB-PET signal observed in our ADCI cohort may be more a 
measure of parenchymal A (this being the predominant signal) and be unrepresentative of 
the true vascular A; PiB-PET binding has been shown to be lower in patients with CAA 
compared to those with AD (Johnson et al., 2007). Thus it is possible that any sequelae of 
vascular amyloid deposition, for example impaired interstitial fluid drainage secondary to a 
failure to adequately clear pathological proteins, could still be visible as MRI-visible CSO-
PVS (Weller et al., 2015), independently of PiB positivity.  
An alternative explanation is that CSO-PVS are associated with ADCI but not PiB positivity 
because they are manifestations of an amyloid-independent process, for example a tau protein 
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related process. As well as being a core neuropathological finding in AD, neurofibrillary 
tangles have been demonstrated in association with CAA in patients with AD (Jeynes and 
Provias, 2006), and tau deposits (neurofibrillary tangles and pretangles) have been described 
in Aβ-related angiitis, an inflammatory form of CAA (Kurian et al., 2012). One study 
reviewing perivascular hyperphosphorylated tau in patients with AD found higher levels 
surrounding the CAA affected vessels than the unaffected ones (Williams et al., 2005). Thus 
it is possible that CAA could impair perivascular drainage, leading to tau aggregation, which 
could further impair perivascular drainage leading to further tau aggregation and so on (a 
“feed-forward” loop), with MRI-visible perivascular spaces being the end result (Weller et 
al., 2009; Love and Miners, 2015).  In animal models, traumatic brain injury appears to 
disrupt normal perivascular clearance for at least 28 days, resulting in the accumulation of 
hyper-phosphorylated tau (Iliff et al., 2014); CAA could impair perivascular drainage in a 
similar way. Alternatively CAA may disrupt perivascular drainage via perturbations in 
normal arteriolar pulsation (Hawkes et al., 2014; Kress et al., 2014). It is also possible that 
the presence of hyper-phosphorylated tau has direct deleterious consequences for perivascular 
astrocytes, for example by directly disrupting their microtubular structure, or altering the 
expression or localisation of membrane channels (for example, aquaporin 4) that change 
normal interstitial fluid dynamics, with the eventual outcome of an enlarged perivascular 
space (Arima et al., 1998; Thrane et al., 2014; Iqbal et al., 2016).  
 
This study has some limitations. Firstly, this is an observational study without healthy aged 
matched controls for comparison; despite this, our findings are generally in keeping with 
previous reports from AD and SVCI cohorts. A previous study (Charidimou et al., 2015) has 
demonstrated an association between PiB positivity and CSO-PVS across a cohort including 
healthy controls (both aged over and under 60 years) and patients with CAA-related ICH; 
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interestingly although those with CAA had a higher burden of CSO-PVS compared with the 
healthy control groups (p=0.08), there did not appear to be a difference in PiB positivity 
between healthy older patients and CAA (p=0.53). This may provide further evidence that 
CSO-PVS burden is a closer correlate of vascular amyloid burden than PiB-PET measures 
are, but it is difficult to draw firm conclusions as this study included only 31 participants 
(Charidimou et al., 2015). Additionally, our findings may only be applicable to a selected 
memory clinic population, specifically those with either AD related cognitive impairment or 
SVCI, rather than the full spectrum of dementia syndromes. Our project would also have 
strengthened if participants had other measures of Aβ burden in addition to amyloid-PET, for 
example quantification of CSF or serum Aβ. Certain measures, for example the ratio of 
Aβ40:42 (Verbeek et al., 2009), may better capture vascular Aβ and thus might demonstrate 
with CSO-PVS. It was not possible to draw any conclusions on whether the association 
between AD diagnosis and CSO-PVS severity was due to any form of CAA. Only small 
numbers within our cohort had characteristics known to be associated with haemorrhage-
associated CAA (type 2), namely an APOE ε2 allele (notably, none of the cohort were 
homozygous for APOE ε2), strictly lobar microbleeds and cSS; however, given that over 
95% of those with AD have pathological evidence of CAA  it may be that the predominant 
CAA subtype in AD is type 1, which is associated with APOE ε4 and capillary level disease 
(Charidimou et al., 2012). Thus it may be the case that more traditional “haemorrhagic” 
markers of CAA are of less clinical relevance in this population.  
 
This study provides further supporting evidence that CSO-PVS are a key imaging marker for 
AD, but without being a measure of amyloid positivity as measured by PiB PET. This raises 
the possibility that CSO-PVS are a measure of vascular amyloid processes that are not 
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identified by amyloid-PET, or alternatively of an amyloid independent process, or both. 
Future work reviewing the association between CSO-PVS and other circulating biomarkers 
of Aβ burden, and the relationship between tau and CAA will be necessary to further clarify 
the mechanisms underlying these findings.  
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Tables & Figures 
Table 1: Baseline characteristics according to disease classification (p values reflect 
comparisons between ADCI and SVCI groups using Chi-squared, Fishers exact, 
independent t-tests or Mann-Whitney U tests as appropriate). 
 
All ADCI SVCI p value 
n (%) 226 110 (48.7%) 116 (51.3%) - 
Age, years, mean (SD) 72.1 (8.1) 70.3 (8.8) 73.8 (7.0) 0.0012 
Sex, male, n (%) 98 (43.4%) 49 (44.6%) 49 (42.3%) 0.727 
Hypertension, n (%) 142 (62.8%) 52 (47.3%) 90 (77.6%) <0.0001 
Diabetes Mellitus, n (%) 45 (19.9%) 15 (13.6%) 30 (25.9%) 0.021 
Hyperlipidemia, n (%) 68 (30.1%) 26 (23.6%) 42 (36.2%) 0.039 
Prior stroke, n (%) 37 (16.4%) 6 (5.4%) 31 (26.7%) <0.0001 
     
PiB Positivity, n (%) 120 (53.1%) 86 (78.2%) 34 (29.3%) <0.0001 
     
Presence of APOE ε2, n (%) 22 (10.0%) 7 (6.5%) 15 (13.3%) 0.096 
Presence of APOE ε3, n (%) 203 (92.3%) 93 (86.9%) 110 (97.4%) 0.004 
Presence of APOE ε4, n (%) 81 (36.8%) 52 (48.6%) 29 (25.7%) <0.0001 
     
Lacunes, median (IQR) 1 (0 - 9) 0 (0 - 0) 9 (3.5 - 17) <0.0001 
cSS presence, n (%) 8 (3.5%) 5 (4.6%) 3 (2.6%) 0.426 
Strictly lobar CMB (presence), n (%) 17 (7.5%) 7 (6.4%) 10 (8.6%) 0.520 
Deep CMB (presence), n (%) 69 (30.8%) 7 (6.5%) 62 (53.5%) <0.0001 
     
CSO-PVS 
    
None/Mild (grade 0 - 1), n (%) 73 (32.3%) 16 (14.6%) 57 (49.1%) 
<0.0001 Moderate (grade 2), n (%) 91 (40.3%) 49 (44.6%) 42 (36.2%) 
Frequent / Severe (grade 3 - 4), n (%) 62 (27.4%) 45 (40.9%) 17 (14.7%) 
     
BG-PVS 
    
None/Mild (grade 0 - 1), n (%) 170 (75.2%) 103 (93.6%) 67 (57.57%) 
<0.0001 Moderate (grade 2), n (%) 44 (19.5%) 6 (5.4%) 38 (32.8%) 
Frequent / Severe (grade 3 - 4), n (%) 12 (5.3%) 1 (0.91%) 11 (9.48%) 
 
Abbreviations: 
ADCI Alzheimer’s disease related cognitive impairment 
APOE Apolipoprotein E 
28 
 
BG Basal ganglia 
CSO Centrum semi-ovale 
cSS Cortical superficial siderosis 
CMB Cerebral microbleed 
IQR Interquartile range 
PiB 11-Carbon based Pittsburgh compound B 
PVS Perivascular space (MRI-visible) 
SD Standard deviation 
SVCI Subcortical vascular cognitive impairment
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Table 2: Logistic regression analysis for predictors of clinical diagnosis (ADCI group) 
 
Univariable Multivariable (CSO) Multivariable (BG) 
 
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value 
CSO-PVS: 
None/Mild (grade 0 - 1)  
Moderate (grade 2) 
Frequent / Severe (grade 3 - 4) 
 
Reference Group 
4.16 (2.08 to 8.29) 
9.43 (4.29 to 20.71) 
<0.00001 
 
Reference Group 
3.57 (1.17 to 10.89) 
6.26 (1.66 to 23.58) 
5.40 (2.02 to 14.45) 
7.69 (2.54 to 23.30) 
0.0003 
0.017 
- - 
BG-PVS: 
None/Mild (grade 0 - 1)  
Moderate (grade 2) 
Frequent / Severe (grade 3 - 4) 
 
Reference Group 
0.10 (0.04 to 0.26) 
0.06 (0.01 to 0.47) 
<0.00001 - - 
 
Reference Group 
0.26 (0.07 to 1.01) 
0.03 (0.00 to 0.44) 
0.14 (0.04 to 0.45) 
0.05 (0.00 – 0.53) 
0.009 
0.0004 
 
  
     
Age (for each year older) 0.95 (0.91 to 0.98) 0.002 
0.94 (0.88 to 1.01) 
0.92 (0.87 to 0.98) 
0.091 
0.006 
0.95 (0.88 to 1.03) 
0.93 (0.88 to 0.99) 
0.214 
0.021 
Hypertension (presence) 0.26 (0.15 to 0.46) <0.0001 
1.13 (0.39 to 3.28) 
0.78 (0.32 to 1.91) 
0.828 
0.580 
1.04 (0.35 to 3.11) 
0.79 (0.32 to 1.93) 
0.951 
0.604 
Diabetes (presence) 0.45 (0.23 to 0.90) 0.023 
0.45 (0.14 to 1.44) 
0.69 (0.26 to 1.84) 
0.180 
0.457 
0.42 (0.13 to 1.36) 
0.79 (0.30 to 2.08) 
0.149 
0.630 
Hyperlipidaemia (presence) 0.55 (0.31 to 0.97) 0.041 
0.39 (0.14 to 1.11) 
0.42 (0.17 to 1.02) 
0.077 
0.057 
0.53 (0.18 to 1.55) 
0.50 (0.21 to 1.19) 
0.247 
0.115 
Prior stroke (presence) 0.16 (0.06 to 0.40) <0.0001 
0.55 (0.12 to 2.56) 
0.49 (0.15 to 1.62) 
0.444 
0.245 
0.53 (0.12 to 2.28) 
0.47 (0.15 to 1.50) 
0.396 
0.204 
  
     
PiB positivity (presence) 8.64 (4.72 to 15.81) <0.0001 
3.97 (1.46 to 10.80) 
6.72 (2.83 to 15.96) 
0.007 
<0.0001 
5.63 (1.96 to 16.21) 
8.69 (3.53 to 21.39) 
0.001 
<0.0001 
APOE ε2 (presence) 0.46 (0.18 to 1.17) 0.103 - - - - 
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APOE ε3 (presence) 0.18 (0.05 to 0.65) 0.009 
0.47 (0.05 to 4.31) 
0.60 (0.10 to 3.66) 
0.507 
0.576 
0.29 (0.03 to 2.73) 
0.28 (0.04 to 1.92) 
0.277 
0.193 
APOE ε4 (presence) 2.73 (1.55 to 4.83) 0.001 
0.82 (0.28 to 2.40) 
1.17 (0.47 to 2.88) 
0.722 
0.739 
0.65 (0.21 to 1.99) 
0.89 (0.35 to 2.24) 
0.449 
0.807 
  
     
Lacunes (per additional 
lacunefor one number higher) 
 
0.49 (0.39 to 0.61) <0.0001 0.61 (0.48 to 0.78) <0.0001 0.59 (0.47 to 0.75) <0.0001 
cSS (presence) 1.79 (0.42 to 0.69) 0.432 - - - - 
Strictly lobar CMB (presence) 0.72 (0.26 to 1.96) 0.522 - - - - 
Deep CMB (presence) 0.06 (0.03 to 0.14) <0.0001 
0.45 (0.11 to 1.75) 
0.10 (0.03 to 0.27) 
0.247 
<0.0001 
0.59 (0.14 to 2.54) 
0.11 (0.04 to 0.32) 
0.478 
<0.0001 
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Table 3: Baseline Characteristics for PiB positive and negative groups (p values 
reflect comparisons between PiB positive and negative groups using Chi-squared, 
Fishers exact, independent t-tests or Mann-Whitney U tests as appropriate). 
 
PiB Negative 
(retention ratio < 
1.5) 
PiB Positive 
(retention ratio ≥ 
1.5) 
p value 
n (%) 106 (46.9%) 120 (53.1%) - 
Age, years, mean (SD) 72.0 (7.2) 72.2 (8.8) 0.808 
Sex, male, n (%) 48 (45.3%) 50 (41.7%) 0.584 
Hypertension, n (%) 82 (77.4%) 60 (50.0%) <0.0001 
Diabetes Mellitus, n (%) 27 (25.5%) 18 (15.0%) 0.049 
Hyperlipidemia, n (%) 37 (34.9%) 31 (25.8%) 0.138 
Prior stroke, n (%) 27 (25.5%) 10 (8.3%) 0.001 
    
ADCI, n (%) 24 (22.6%) 86 (71.7%) <0.0001 
SVCI, n (%) 82 (77.4%) 34 (28.3%) <0.0001 
    
Presence of APOE ε2, n (%) 14 (13.6%) 8 (6.8%) 0.096 
Presence of APOE ε3, n (%) 102 (99.0%) 101 (86.3%) <0.0001 
Presence of APOE ε4, n (%) 18 (17.5%) 63 (53.9%) <0.0001 
    
WMH volume, ml, median (IQR) 29.9 (13.6 – 45.5) 5.2 (1.2 – 26.2) <0.00001 
Lacunes, median (IQR) 7 (1 – 17) 0 (0 – 2) <0.00001 
cSS presence, n (%) 1 (0.9%) 7 (5.8%) 0.047 
Strictly lobar CMB (presence), n (%) 7 (6.6%) 10 (8.3%) 0.623 
Deep CMB (presence), n (%) 49 (46.7%) 20 (16.8%) <0.0001 
    
CSO-PVS 
   
None/Mild (grade 0 - 1), n (%) 41 (38.7%) 32 (26.7%) 
0.033 Moderate (grade 2), n (%) 44 (41.5%) 47 (39.2%) 
Frequent / Severe (grade 3 - 4), n (%) 21 (19.8%) 41 (34.2%) 
    
BG-PVS 
   
None/Mild (grade 0 - 1), n (%) 76 (71.7%) 94 (78.3%) 
0.480 Moderate (grade 2), n (%) 23 (21.7%) 21 (17.5%) 
Frequent / Severe (grade 3 - 4), n (%) 7 (6.6%) 5 (4.2%) 
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Table 4: Logistic regression analysis for predictors of PiB positivity 
 
Univariable Multivariable 
 
OR (95% CI) p value OR (95% CI) p value 
CSO-PVS: 
None/Mild (grade 0 - 1) 
Moderate (grade 2) 
Frequent / Severe (grade 3 - 4) 
 
Reference Group 
1.37 (0.74 to 2.54) 
2.50 (1.24 to 5.04) 
0.032 
 
Reference Group 
0.67 (0.29 to 1.59) 
0.93 (0.35 to 2.46) 
0.607 
BG-PVS: 
None/Mild (grade 0 - 1) 
Moderate (grade 2) 
Frequent / Severe (grade 3 - 4) 
 
Reference Group 
0.74 (0.38 to 1.43) 
0.58 (0.18 to 1.89) 
0.480 - - 
  
   
Hypertension (presence) 0.29 (0.16 to 0.52) <0.0001 0.52 (0.24 to 1.10) 0.085 
Diabetes (presence) 0.52 (0.27 to 1.00) 0.051 0.97 (0.42 to 2.26) 0.947 
Previous stroke (presence) 0.27 (0.12 to 0.58) 0.001 0.48 (0.17 to 1.33) 0.157 
  
   
ADCI diagnosis 8.64 (4.72 to 15.81) <0.0001 7.56 (2.59 to 22.46) <0.0001 
APOE ε2 (presence) 0.47 (0.19 to 1.16) 0.102   
APOE ε3 (presence) 0.06 (0.01 to 0.48) 0.007 0.25 (0.03 to 2.29) 0.221 
APOE ε4 (presence) 5.51 (2.95 to 10.29) <0.0001 3.87 (1.80 to 8.32) 0.001 
  
   
WMH volume (for each ml higher) 0.97 (0.96 to 0.98) <0.0001 1.03 (1.00 to 1.05) 0.055 
Lacunes (for one number higher) 0.88 (0.83 to 0.92) <0.0001 0.94 (0.88 to 0.99) 0.026 
     
cSS (presence) 6.50 (0.79 to 53.76) 0.082 - - 
Strictly lobar CMB (presence) 1.29 (0.47 to 3.51) 0.623 - - 
Deep CMB (presence) 0.23 (0.12 to 0.43) <0.0001 1.07 (0.43 to 2.65) 0.886 
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Figure 1: Examples of MRI-visible perivascular spaces. 
[A - C] Examples of MRI-visible CSO-PVS, [A] None/Mild grade, [B] Moderate grade, [C] Frequent/Severe grade 
[D - F] Examples of MRI-visible BG-PVS, [D] None/Mild grade, [E] Moderate grade, [F] Frequent/Severe grade 
Figure now included as separate TIFF file, as per author instructions.  
 
